Please assess the completion status of the following clinical trial:

Trial Title: Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female minimum 18 years of age~* Not less than 6 months on hemodialysis~* Cardiovascular calcification percent (coronary artery volume score \> 100)~* Written consent to take part in the study~* Life expectancy not less than 18 months~Exclusion Criteria:~* Known hypersensitivity against Vitamin K1~* History of thrombosis~* intake of Vitamin K~* tumor disease~* pulse \>100/min (resting heart rate)~* Intake of vitamin K antagonists (e.g. Marcumar) at baseline or in the 3 months prior to baseline~* Inflammatory bowel disease~* Short-bowel syndrome~* Significant liver dysfunction~* more than one stent in one coronary artery plus one or more stents in an additional artery~* Hemoglobin \< 70 g/L~* Women who are pregnant or breastfeeding~* Women without sufficient contraception~* Alcohol or drug abuse~* Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study~* Subject unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up-visits and unlikelihood of completing the study~* Participation in a parallel clinical trial or participation in another clinical trial within the previous 3 months~* Subjects who are in any state of dependency to the sponsor or the investigators~* Employees of the sponsor or the investigators~* Subjects who have been committed to an institution by legal or regulatory order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard treatment (usual care) (Type: NO_INTERVENTION): standard treatment (usual care)
- Vitamin K1 (Type: EXPERIMENTAL): Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).